Genflow Biosciences Plc (GB:GENF)
LSE:GENF
Top Page
Genflow Biosciences Plc
(LSE:GENF)
Select Model
Select Model
Rating:47Neutral
Price Target:
2.00 p
▼(-11.11% Downside)
Action:N/ADate:01/04/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.
Genflow Biosciences Plc (GENF) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£9.37M
Dividend YieldN/A
Average Volume (3M)1.73M
Price to Earnings (P/E)―
Beta (1Y)-0.08
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding535,653,200
10 Day Avg. Volume2,042,393
30 Day Avg. Volume1,733,703
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)-14.36
Price to Sales (P/S)0.00
P/FCF Ratio-5.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genflow Biosciences Plc Business Overview & Revenue Model
Company Description
Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with...
How the Company Makes Money
null...
Genflow Biosciences Plc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -150.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -150.95K | -1.20K | -1.03K | -130.00 | 0.00 | 0.00 |
| EBITDA | -1.27M | -1.59M | -1.80M | -1.33M | -988.10K | -1.09K |
| Net Income | -1.27M | -1.59M | -1.63M | -1.34M | -988.29K | -651.01K |
Balance Sheet | ||||||
| Total Assets | 468.38K | 385.91K | 1.07M | 2.62M | 276.55K | 283.78K |
| Cash, Cash Equivalents and Short-Term Investments | 279.44K | 278.68K | 683.97K | 2.36M | 224.00K | 254.23K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 771.38K | 788.92K | 345.74K | 250.99K | 221.43K | 64.80K |
| Stockholders Equity | -303.00K | -403.01K | 725.91K | 2.37M | 55.12K | 218.98K |
Cash Flow | ||||||
| Free Cash Flow | -1.28M | -1.08M | -1.66M | -1.37M | -747.38K | -439.46K |
| Operating Cash Flow | -1.28M | -1.08M | -1.66M | -1.37M | -747.38K | -439.46K |
| Investing Cash Flow | 372.00 | 0.00 | -2.44K | -2.48K | 198.50K | 216.55K |
| Financing Cash Flow | 865.22K | 656.63K | 0.00 | 3.50M | 783.71K | 1.96M |
Genflow Biosciences Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | £2.13M | -0.72 | -89.43% | ― | 44.32% | 60.00% | |
47 Neutral | £9.37M | -1.89 | 377.33% | ― | ― | ― | |
44 Neutral | £15.94M | -9.67 | -210.32% | ― | -11.43% | 23.40% | |
41 Neutral | £78.97M | -4.89 | -63.53% | ― | 198.49% | -26.66% | |
40 Underperform | £8.80M | -0.25 | -316.67% | ― | 72.17% | 79.03% | |
40 Underperform | £16.18M | -6.19 | -213.66% | ― | 39.88% | 81.33% |
* Healthcare Sector Average
GB:GENF
Genflow Biosciences Plc
1.75
0.60
52.17%
GB:OBD
Oxford BioDynamics
0.21
-0.28
-57.29%
GB:PYC
Physiomics
0.47
0.04
9.30%
GB:FAB
Fusion Antibodies Plc
12.75
6.25
96.15%
GB:4BB
4basebio UK Societas
510.00
-615.00
-54.67%
GB:APTA
Aptamer Group Plc
0.60
0.33
122.22%
Genflow Biosciences Plc Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Genflow Biosciences Raises £800,000 to Advance Gene Therapy Pipeline and Bolster Licensing Talks
Positive
Mar 5, 2026
Genflow Biosciences has raised £800,000 through a subscription of 42,105,263 new ordinary shares at 1.9p each, with one warrant attached per share, to fund the advancement of its scientific programs and extend its cash runway. The financing, ...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Genflow Wins Shareholder Backing for Expanded Financing Flexibility
Positive
Mar 2, 2026
Genflow Biosciences Plc, a UK-based longevity-focused biotechnology company listed in London and on OTCQB, is developing gene therapies such as its lead candidate GF-1002, which targets aging-related conditions and is under evaluation in an aged-d...
Business Operations and StrategyPrivate Placements and Financing
Genflow Receives First Tranche of €4m Wallonia Grant to Advance GF-1002
Positive
Mar 2, 2026
Genflow Biosciences Plc, a longevity-focused gene therapy developer based in the UK with Belgian RD operations, is advancing its lead asset GF-1002, which targets age-related decline via a centenarian SIRT6 variant and is under evaluation in canin...
Business Operations and StrategyProduct-Related Announcements
Genflow Reports Positive Interim Data for SIRT6 Gene Therapy in Aged Dogs
Positive
Feb 12, 2026
Genflow Biosciences has reported positive preliminary interim results from its SLAB clinical trial testing its proprietary SIRT6 centenarian gene therapy in 24 aged beagle dogs. The randomized, blinded study found that all treatment groups showed ...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Genflow Seeks Shareholder Mandate for Potential Equity Raise to Advance Gene Therapy Pipeline
Neutral
Feb 11, 2026
Genflow Biosciences plans to seek shareholder approval at a 2 March 2026 general meeting to authorize the issue of up to 188,947,368 new ordinary shares, equivalent to about 38% of its current share capital. The authority would allow the board to ...
Business Operations and StrategyPrivate Placements and Financing
Genflow Secures €4m Wallonia Funding and Sets 2026 Gene Therapy Priorities
Positive
Jan 28, 2026
Genflow Biosciences has received administrative approval for approximately €4 million in non-dilutive funding support from Belgium’s Wallonia region to advance its lead gene therapy, GF-1002, for the treatment of MASH, with the three-y...
Business Operations and StrategyExecutive/Board Changes
Genflow Biosciences Names Gad Berdugo Chairman to Drive Next Phase of Gene Therapy Growth
Positive
Jan 19, 2026
Genflow Biosciences has appointed Gad Berdugo as Independent Non-Executive Chairman, a move aimed at accelerating the company’s corporate development and RD strategy as it advances its gene-therapy programs for age-related diseases. Berdugo&...
Business Operations and Strategy
Genflow Biosciences Caps 2025 With Key Gene Therapy Milestones and Sets 2026 Partnership Push
Positive
Jan 8, 2026
Genflow Biosciences reported a year of scientific and clinical progress in 2025, highlighting completion of dosing in its blinded SIRT6-based gene therapy trial in aging dogs without observed adverse events, with initial efficacy data expected in ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.